Eli Lilly and Company $LLY Stock Sold by Hager Investment Management Services LLC

Posted by Brenda Bartman on Nov 9th, 2026

Eli Lilly and Company logo Hager Investment Management Services LLC trimmed its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 8.6% in the third quarter, Holdings Channel reports. The firm owned 4,200 shares of the company’s stock after selling 393 shares during the quarter. Eli Lilly and Company comprises approximately 2.3% of Hager Investment Management Services LLC’s investment portfolio, making the stock its 9th biggest position. Hager Investment Management Services LLC’s holdings in Eli Lilly and Company were worth $4,860,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Brickley Wealth Management lifted its stake in Eli Lilly and Company by 23.8% in the 3rd quarter. Brickley Wealth Management now owns 302 shares of the company’s stock valued at $349,000 after purchasing an additional 58 shares during the last quarter. Avion Wealth increased its position in Eli Lilly and Company by 1.0% during the third quarter. Avion Wealth now owns 780 shares of the company’s stock worth $902,000 after buying an additional 8 shares during the last quarter. Hohimer Wealth Management LLC increased its position in Eli Lilly and Company by 1.5% during the third quarter. Hohimer Wealth Management LLC now owns 1,788 shares of the company’s stock worth $2,069,000 after buying an additional 27 shares during the last quarter. University of Texas Texas AM Investment Management Co. increased its position in Eli Lilly and Company by 6.6% during the third quarter. University of Texas Texas AM Investment Management Co. now owns 1,187 shares of the company’s stock worth $1,373,000 after buying an additional 73 shares during the last quarter. Finally, Triune Financial Partners LLC raised its stake in Eli Lilly and Company by 1.7% in the third quarter. Triune Financial Partners LLC now owns 524 shares of the company’s stock valued at $606,000 after buying an additional 9 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. The trade was a 54.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Up 1.3%

Eli Lilly and Company stock opened at $1,372.15 on Monday. The company’s 50-day moving average price is $1,215.24 and its two-hundred day moving average price is $1,101.16. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. The stock has a market cap of $1.29 trillion, a P/E ratio of 44.54, a P/E/G ratio of 1.62 and a beta of 0.40. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,453.00.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. During the same quarter in the previous year, the company posted $7.02 earnings per share. The business’s revenue was up 38.6% on a year-over-year basis. As a group, analysts expect that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 22.46%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Lilly and Hims & Hers agreed to offer FDA-approved Zepbound and Foundayo through Hims & Hers’ telehealth platform. Eligible patients with a prescription can access Lilly’s self-pay prices—reportedly starting at $149—without leaving the platform. The deal could widen patient access and Lilly’s reach in the competitive obesity-treatment market. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
Positive Sentiment: New Phase 3 results for investigational retatrutide showed substantial reductions in weight and knee pain among adults with obesity and knee osteoarthritis. Lilly also reported positive Phase 3b results for combining Taltz and Zepbound in people with psoriatic arthritis and obesity, supporting the potential of its medicines in additional patient groups. Lilly to showcase new retatrutide, Taltz and Zepbound data
Negative Sentiment: Price competition across the GLP-1 market remains a risk to Lilly’s growth and drug margins, as branded treatments compete with lower-priced options and providers seek self-pay patients. Eli Lilly’s GLP-1 franchise faces growing price competition

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on LLY. BMO Capital Markets reaffirmed an “outperform” rating and issued a $1,650.00 price objective on shares of Eli Lilly and Company in a research report on Friday, October 30th. Scotiabank boosted their target price on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a “sector outperform” rating in a report on Friday, October 30th. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Guggenheim raised their price target on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a report on Friday, September 18th. Finally, Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $1,404.14.

Get Our Latest Analysis on Eli Lilly and Company

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.